Skip to content
OpenCapital
Get started

Supernus Pharmaceuticals SUPN Cash Provided by (Used in) Financing Activity, Including Discontinued Operation

Cash Provided by (Used in) Financing Activity, Including Discontinued Operation at other companies

Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
-$78.5M+90.4%
Bausch Health Companies logo
Bausch Health CompaniesBHC
-$100M+31.5%

Other financials

Income statement

See full
Revenue$207.7M+38.6%
Gross profit$184.3M+37.5%
Operating income-$8.3M+18.8%
Net income-$2.3M+80.6%
EPS (diluted)-$0.04+81.0%

Balance sheet

See full
Cash & equivalents$186.3M+60.8%
Total debt$40.9M+26.6%
Total equity$1.1B+4.5%
Total assets$1.5B+11.4%

Cash flow

See full
Operating cash flow$66.5M+117%
CapEx--100%
Free cash flow$66.5M+120%

Valuation

See full
Market cap$2.62B+62.8%

Profitability

See full
Gross margin89.4%+1.0pp
Operating margin-7.8%-18.9pp
Net margin-3.7%-13.0pp
FCF margin27.9%+3.4pp

Returns & leverage

See full
Return on equity-2.8%-9.1pp
Debt / equity0×0.0×
Current ratio2×-0.5×

Where this comes from

Reported directly by Supernus Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Supernus Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Supernus Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
Supernus Pharmaceuticals (SUPN) reported cash provided by (used in) financing activity, including discontinued operation of $9.12M in Q1 2026.
How has Supernus Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation changed year-over-year?
Supernus Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation increased by 142.6% year-over-year, from -$21.4M to $9.12M.
What is the long-term trend for Supernus Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation?
Over 3 years (2021 to 2025), Supernus Pharmaceuticals's cash provided by (used in) financing activity, including discontinued operation has grown at a -58.8% compound annual growth rate (CAGR), from -$130.42M to $9.13M.
What does cash provided by (used in) financing activity, including discontinued operation mean?
This metric measures the net cash flow between the company and its capital providers, including proceeds from debt or equity issuance and payments for dividends or share repurchases. It highlights how the company finances its operations and returns value to shareholders.